StockNews.AI
WST
StockNews.AI
180 days

West Announces Second-Quarter Dividend

1. WST announces Q2 2025 dividend. Dividend set at $0.21 per share. 2. Board approved the dividend. Payment is scheduled for May 7, 2025. 3. The announcement reinforces WST’s steady financial discipline. It builds shareholder confidence. 4. Company highlights global operations and manufacturing scale. It underlines its leadership in injectable solutions.

+3.56%Current Return
VS
-1.72%S&P 500
$203.6502/20 04:36 PM EDTEvent Start

$210.9102/21 10:50 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Neutral?

Dividend announcements from established firms typically have minimal short-term pricing effects. Historical trends in mature dividend payers show limited volatility on such news.

How important is it?

The dividend payout signals financial stability and rewards shareholders but is unlikely to drive major price changes. Its routine nature in a mature company results in moderate relevance.

Why Short Term?

Dividend-related price adjustments, such as ex-dividend drops, result in short-term movement. The designated payout date may induce transient trading behavior.

Related Companies

, /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, announced today that the Company's Board of Directors has approved a second-quarter 2025 dividend of $0.21 per share. The dividend will be paid on May 7, 2025, to shareholders of record as of April 30, 2025. About West  West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With over 10,000 team members across 50 sites including 25 manufacturing facilities worldwide, West helps support our customers by delivering over 41 billion components and devices each year. Headquartered in Exton, Pennsylvania, West in its fiscal year 2024 generated $2.89 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor's 500 index. For more information, visit www.westpharma.com. All trademarks and registered trademarks used in this release are the property of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions, unless otherwise noted. SOURCE West Pharmaceutical Services, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News